MGUS: Symptoms, Causes & Diagnosis
- What: The first FDA-approved vaccines to prevent respiratory syncytial virus (RSV), a common and possibly serious respiratory illness.
- Where: United States, with potential global rollout pending regulatory approvals.
- When: Approved in May 2023, with initial rollout beginning in fall 2023 and expanded availability in Fall 2025.
“`html
RSV Vaccine Breakthrough: Protecting Infants and Older Adults
Understanding RSV: A Threat Across the Lifespan
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. however, for infants, young children, and older adults, RSV can lead to severe illness, including bronchiolitis and pneumonia. Before the growth of these vaccines, RSV was responsible for an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually in the United States among older adults, and a significant number of hospitalizations in young children.
The virus spreads through close contact with infected individuals, similar to the common cold. Symptoms typically appear 4-6 days after infection and include a runny nose, decreased appetite, cough, sneezing, fever, and wheezing. While most people recover within a week or two,vulnerable populations face a higher risk of complications.
The Landmark Vaccine Approvals: A Two-Pronged Approach
In May 2023, the Food and drug Administration (FDA) approved two groundbreaking RSV vaccines: Arexvy, developed by GSK, and Abrysvo, developed by Pfizer. These approvals represent a major public health achievement after decades of research. The vaccines utilize diffrent technologies, offering distinct advantages for different age groups.
Arexvy (GSK): This vaccine is approved for adults aged 60 years and older. It utilizes a recombinant subunit vaccine approach, presenting a stabilized prefusion F protein to stimulate an immune response. Clinical trials demonstrated approximately 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) in this population.
Abrysvo (Pfizer): Abrysvo received a broader approval, encompassing both older adults (60 years and older) and pregnant individuals. for pregnant people, the vaccine is administered between 32 and 36 weeks of gestation, aiming to protect their infants through the transfer of antibodies. Clinical trials showed approximately 77.3% efficacy in preventing severe LRTD in infants during their first three months of life. It also demonstrated 81.8% efficacy in preventing RSV-associated LRTD in older adults.
Clinical Trial Data: Efficacy and safety Profiles
The efficacy of both vaccines was rigorously evaluated in large-scale, randomized, placebo-controlled clinical trials. The trials, conducted across multiple sites, involved thousands of participants. Key findings are summarized below:
| Vaccine | Target Population | Efficacy (LRTD) | Notable Safety Concerns |
|---|---|---|---|
| Arexvy (GSK) | Adults 60+ | 82.6% | Local reactions (pain, redness at injection site), fatigue, muscle pain. rare cases of Guillain-Barré syndrome were observed. |
| abrysvo (Pfizer) | Adults 60+ | 81.8% | Local reactions, fatigue, muscle pain. Increased incidence of medical conditions requiring hospitalization in the vaccine group was observed in some trials, but causality remains under examination. |
| Abrysvo (Pfizer) |